The diagnostic yield of pancreatic ductal adenocarcinoma was substantial in high-risk mutation carrier but non-existent in mutation-negative proven familial pancreatic cancer kindreds.
“Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with [endoscopic ultrasonography (EUS)] outperforming [MRI/cholangiopancreatography (MRI/MRCP)],” Kasper A. Overbeek, MD, from the department of gastroenterology and hepatology and the Erasmus MC Cancer Institute, Erasmus University Medical Center in Rotterdam, the Netherlands, and colleagues wrote. “Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.”